	Application No.	Applicant(s)
Notice of Allowability	10/081,713 Examiner	PLATA-SALAMAN ET AL. Art Unit
	Framilie	
	Phyllis G. Spivack	1614
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to the Amendment filed March 24, 2005.		
2. The allowed claim(s) is/are <u>26-46 and 48.</u>		
3. The drawings filed on are accepted by the Examiner.		
4. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some* c) None of the: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No.		
3. Copies of the certified copies of the priority documents have been received in this national stage application from the		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
5. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
6. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) 🗌 hereto or 2) 🔲 to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
7. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s) 1. Notice of References Cited (PTO-892)	5 Notice of Informal P	atent Application (PTO-152)
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6. ☐ Interview Summary	'''
3. Information Disclosure Statements (PTO-1449 or PTO/SB/08	Paper No./Mail Dat	e
Paper No./Mail Date 4. Examiner's Comment Regarding Requirement for Deposit	8 🕅 Evaminar's Stateme	nt of Reasons for Allowance
of Biological Material	9. ☐ Other	o. reasons for Allowance
	J	

EXAMINER'S AMENDMENT

An Examiner's Amendment to the record appears below. Should the changes and/or additions be unacceptable to Applicants, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

The first line of the Abstract is <u>deleted</u> and -- Methods for treating an Impulse Control Disorder -- is <u>inserted</u> therefor. On line 2 "disorders" is <u>deleted</u> and -- are disclosed -- is <u>inserted</u> therefor. Parenthesis are deleted on lines 6 and 8 under the Formulas.

REASONS FOR ALLOWANCE

An Amendment filed March 24, 2005 is acknowledged. Claim 47 is canceled. Claims 26-46 and 48 remain under consideration.

A new title is noted.

Subsequent to the cancellation of claim 47, the rejection of record under 35 U.S.C. 102(a) is moot.

In the last Office Action claims 26, 29, 45, 46 and 48 were rejected under 35 U.S.C 103 as being unpatentable over Bossinger et al., U.S. Patent 3,313,692. It was asserted Bossinger teaches the administration of compounds of instant Formula II for inducing a calming effect.

Application/Control Number: 10/081,713

Art Unit: 1614

Applicants argue the property of inducing sedation or calming and the property of controlling the impulsive behavior that is characteristic of an Impulse Control Disorder are separate clinically and from a biochemical and/or neurological prospective.

Applicants' argument is persuasive and the rejection of record under 35 U.S.C. 103 is withdrawn.

There is no motivation or suggestion in the prior art to apply the teachings of Bossinger to treating an Impulse Control Disorder. Accordingly, claims 26-46 and 48 are allowed in view of the contemporary knowledge of the art.

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Phyllis G. Spivack whose telephone number is 571-272-0585. The Examiner can normally be reached Mondays to Fridays from 10:30 AM to 7 PM.

If attempts to reach the Examiner by telephone are unsuccessful after one business day, the Examiner's supervisor, Chris Low, can be reached at telephone number 571-272-0951. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should

Application/Control Number: 10/081,713

Art Unit: 1614

Page 4

you have questions on access to the Private PAIR system, contact the Electronic

Business Center (EBC) at 866-217-9197 (toll-free).

Phyllis G. Spivack Primary Examiner Art Unit 1614

PHYLLIS SPIVACK PRIMARY EXAMINER

July 1, 2005